11125

Understanding Zymfentra: The First and Only Subcutaneous Infliximab Offering a New Therapeutic Approach in CD and UC Maintenance

Date
May 21, 2024

Society: DDW

Zymfentra, the first and only subcutaneous infliximab approved by the FDA, now approved for CD and UC. Sponsored by Celltrion Healthcare Co., LTD

Tracks

Related Products

Thumbnail for SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
Thumbnail for PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
Thumbnail for INVESTIGATING THE EFFICACY OF ALPELISIB AND PI3Kα-S6K DUAL INHIBITION IN LIN28B-DRIVEN COLORECTAL CANCER METASTASIS
INVESTIGATING THE EFFICACY OF ALPELISIB AND PI3Kα-S6K DUAL INHIBITION IN LIN28B-DRIVEN COLORECTAL CANCER METASTASIS
Colorectal cancer (CRC) shows a dramatic drop in the five-year survival rate from 90% for localized tumors to 14% for metastatic CRC (mCRC). Our lab has identified LIN28B, an RNA-binding protein overexpressed in 30% of CRCs, as an oncogene that promotes CRC metastasis…
Thumbnail for COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
BACKGROUND: Siewert's topographic classification (SW) has been used for treatment plan of esophagogastric junction adenocarcinomas (EGJA). But recently, molecular classifications categorized EGJA with similar characteristics and prognosis…